Wright Medical Group, Inc. to Host Third Quarter 2012 Earnings Conference Call

  Wright Medical Group, Inc. to Host Third Quarter 2012 Earnings Conference
  Call

      Monday, November 5, 2012 at 3:30 p.m. Central / 4:30 p.m. Eastern

Business Wire

ARLINGTON, Tenn. -- October 17, 2012

Wright Medical Group, Inc. (NASDAQ: WMGI) today announced that it will host a
conference call on Monday, November 5, 2012 at 3:30 p.m. Central Time to
discuss the Company’s operating results for its third quarter ended September
30, 2012. Operating results will be released at 3:00 p.m. Central Time that
day.

The live dial-in number for the call is 800-688-0836 (U.S.) / 617-614-4072
(International). The participant passcode for the call is “Wright.” A
simultaneous webcast of the call will be available via Wright Medical’s
corporate website at www.wmt.com. The call will also be archived on this site
for a minimum of 12 months.

A recording of the call will be available beginning at 5:30 p.m. Central Time
on November 5, 2012 through November 12, 2012. To hear this recording, dial
888-286-8010 (U.S.) / 617-801-6888 (International) and enter code 67114673.

About Wright Medical

Wright Medical Group, Inc. is a global orthopaedic medical device company and
a leading provider of surgical solutions for the foot and ankle market. The
Company specializes in the design, manufacture and marketing of devices and
biologic products for extremity, hip and knee repair and reconstruction. The
Company has been in business for 60 years and markets its products in over 60
countries worldwide. For more information about Wright Medical, visit the
Company’s website at www.wmt.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

The conference call and webcast may contain “forward-looking statements” as
defined under U.S. federal securities laws. These statements reflect
management's current knowledge, assumptions, beliefs, estimates, and
expectations and express management's current view of future performance,
results, and trends. Forward-looking statements may be identified by their use
of terms such as anticipate, believe, could, estimate, expect, intend, may,
plan, predict, project, will, and other similar terms. Forward-looking
statements are subject to a number of risks and uncertainties that could cause
actual results to materially differ from those described in the
forward-looking statements. The reader should not place undue reliance on
forward-looking statements. Such statements are made as of the date of this
press release, and we undertake no obligation to update such statements after
this date. Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements are
discussed in our filings with the Securities and Exchange Commission
(including those described in Item 1A of our Annual Report on Form 10-K for
the year ended December 31, 2011 and our Quarterly Report on Form 10-Q for the
quarter ended June 30, 2012, in each case under the heading “Risk Factors” and
elsewhere in such filings). By way of example and without implied limitation,
such risks and uncertainties include: future actions of the United States
Attorney’s office, the FDA, the Department of Health and Human Services or
other U.S. or foreign government authorities that could delay, limit or
suspend our development, manufacturing, commercialization and sale of
products, or result in seizures, injunctions, monetary sanctions or criminal
or civil liabilities; any actual or alleged breach of the Corporate Integrity
Agreement to which we are subject through September 2015 which could expose us
to significant liability including exclusion from Medicare, Medicaid and other
federal healthcare programs, potential criminal prosecution, and civil and
criminal fines or penalties; adverse outcomes in existing product liability
litigation; new product liability claims; inadequate insurance coverage; the
possibility of private securities litigation or shareholder derivative suits;
demand for and market acceptance of our new and existing products; potentially
burdensome tax measures; lack of suitable business development opportunities;
product quality or patient safety issues; challenges to our intellectual
property rights; geographic and product mix impact on our sales; our inability
to retain key sales representatives, independent distributors and other
personnel or to attract new talent; inventory reductions or fluctuations in
buying patterns by wholesalers or distributors; inability to realize the
anticipated benefits of restructuring initiatives; negative impact of the
commercial and credit environment on us, our customers and our suppliers; and
the potentially negative effect of our ongoing compliance enhancements on our
relationships with customers, and on our ability to deliver timely and
effective medical education, clinical studies, and new products.

Contact:

Wright Medical Group, Inc.
Julie D. Tracy, 901-290-5817
Sr. Vice President, Chief Communications Officer
julie.tracy@wmt.com